How is treatment for head and neck cancer improving?

Written in association with: Mr Taran Tatla
Published: | Updated: 27/07/2023
Edited by: Nicholas Howley

In his  recent online article, highly renowned ENT specialist  Mr Taran Tatla provides an insight into the field of head and neck cancer treatment, the incredible progress we’ve made over the last 40 years, and what patients can expect in the future.

Head and neck cancer is one of the major forms of cancer, accounting for 7-8% of all cancers in the UK. In other countries, this figure is even higher. In Asia, for example, around 30-40% of cancers occur in the head and neck, possibly because of the widespread practice of chewing tobacco, smoking cheap cigarettes and a poor diet. Worldwide, head and neck cancer causes 300,000 deaths every year.

Despite its prevalence, head and neck cancer seems to get far less attention than breast, colon, lung or prostate cancer. Perhaps this is because we are really talking about 30 different types of cancer, all lumped under one banner. Head and neck cancer can include cancer of the mouth, tongue, nose, ear, larynx, and the thyroid gland – and each one is unique in their symptoms and treatment. It isn’t something you can explain easily at a fundraising event.

 

Treatment for head and neck cancer: past and present

The key challenge with treating head and neck cancer is that it is so visible. It can affect our breathing, swallowing, speech, senses, and our appearance. This means that when we look at improving treatment for people with head and neck cancer, we’re not just aiming for better cure rates – our challenge is to restore function and quality of life.

Just 30-40 years ago, treatment for head and neck cancer was primitive. If you survived the treatment, that was a success. Unfortunately many people were left with disfiguring scars, voice and swallowing problems, deafness, or loss of sight.

Since then, we’ve come a long way in restoring function and quality of life to patients. We are now able to reconstruct the voice mechanism to restore speech within three weeks after surgical removal of the voice box. Immunotherapy has become a key part of treatment for some types of cancer and advances in radiotherapy mean we can target tumours more effectively with reduced side effects.

We’ve also come far in terms of diagnosis and awareness. For example, we have seen a decrease in smoking-related mouth cancer among the UK population due to successful public health campaigning. More recently, we were successful in persuading the UK government to introduce the HPV vaccine to teenage boys, as well as girls – a key step in the fight against tonsil cancer.

 

The future of head and neck cancer

Despite these advancements, too many patients still suffer from speech, eating, or breathing difficulties following treatment, so we have improvements to make in this regard. Treatment must also adapt to the changing “face” of head and neck cancer – with more patients who are younger and presenting with tonsil cancer in association with the human papilloma virus (HPV).

It is clear that momentum is building and I am confident we will continue to make great strides in our treatment of patients and ultimately minimise the impact of head and neck cancer on quality of life.

If symptoms and diagnosis are made early, there is an 80-90% chance of cure, but it is important that patients are treated in recognised head and neck cancer centres where cure rates are significantly better than national statistics. It is important to remember that these statistics are historical and they do not necessarily reflect your prospects today. Leading cancer centres are constantly striving to improve survival rates and outcomes and to reduce the adverse side effects of treatment.

Read more: head and neck cancer

By Mr Taran Tatla
Otolaryngology / ENT

Mr Taran Tatla is a highly renowned consultant otorhinolaryngologist in the London area where he practises at his private clinics and with the NHS. He specialises in thyroid disorders, throat and voice-box cancer, breathing difficulties, snoring, neck lumps, swallowing problems, as well as salivary gland disorders. He currently practises at The OneWelbeck, Clementine Churchill Hospital, Centennial Medical Care, and the Northwick Park Hospital Private Patients Unit.

Mr Tatla successfully completed a BSc in anatomy in 1994 and an MBBS in 1996 at the University College London, before going on to notably obtain a Diploma in Laryngology and Otology from The Royal College of Surgeons of England in 2001. He would then kickstart his senior medical career by commencing his NHS consultant post at the established North West London Hospitals NHS Trust, where he first began specialising in ear, nose, and throat disorders, with a special interest in thyroid and head and neck-related conditions and surgery.

He completed a PhD in 2018 linked with the Hamlyn Centre for Robotics, Imperial College London. His main areas of interest include thyroid, parathyroid, and salivary gland disease, nose and sinus disease, breathing and voice disorders, including snoring, swallowing difficulties with specific focus on the effects of reflux disease and allergy. Mr Tatla is, currently, a vital member of the North West London Thyroid and Head and Neck Cancer multi-disciplinary team. He has, thus far, published an extensive amount of peer-reviewed articles and publications, including a major imaging textbook released in 2021.

View Profile

Overall assessment of their patients


  • Related procedures
  • Facelift
    Neck lift
    Otoplasty
    Thread lift
    Buttock lift
    Botulinum toxin (Botox™)
    Dermal fillers
    Facial reconstruction
    Congenital malformations
    Facial plastic surgery
    This website uses our own and third-party Cookies to compile information with the aim of improving our services, to show you advertising related to your preferences as well analysing your browsing habits. You can change your settings HERE.